This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stover, T. C. Articles by Kester, M. Search for Related Content PubMed PubMed Citation Articles by Stover, T. C. Articles by Kester, M.

Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma

Authors' Affiliation: Department of Pharmacology, Pennsylvania State College of Medicine, Hershey, Pennsylvania

Requests for reprints: Mark Kester, Department of Pharmacology, Pennsylvania State College of Medicine, P.O. Box 850, Hershey, PA 17033. Phone: 717-531-8964; Fax: 717-531-5013; E-mail: mxk38{at}psu.edu.

In vitro tumor cell culture models have illuminated the potential therapeutic utility of elevating the intracellular concentration of the antimitogenic and proapoptotic sphingolipid, ceramide. However, although cell-permeable, short-chain ceramide is an effective apoptotic agent in vitro, its use as an in vivo, systemically delivered therapeutic is limited by its inherent lipid hydrophobicity and physicochemical properties. Here, we report that the systemic i.v. delivery of C₆-ceramide (C₆) in a pegylated liposomal formulation significantly limited the growth of solid tumors in a syngeneic BALB/c mouse tumor model of breast adenocarcinoma. Over a 3-week treatment period, a well-tolerated dose of 36 mg/kg liposomal-C₆ elicited a >6-fold reduction in tumor size compared with empty ghost liposomes. Histologic analyses of solid tumors from liposomal-C₆-treated mice showed a marked increase in the presence of apoptotic cells, with a coincident decrease in cellular proliferation and in the development of a microvessel network. Liposomal-C₆ accumulated within caveolae and mitochondria, suggesting putative mechanisms by which ceramide induces selective cancer cell cytotoxicity. A pharmacokinetic analysis of systemic liposomal-C₆ delivery showed that the pegylated liposomal formulation follows first-order kinetics in the blood and achieves a steady-state concentration in tumor tissue. Confirming the therapeutic utility of i.v. liposomal-C₆ administration, we also shown diminution of solid tumor growth in a human xenograft model of breast cancer. Together, these results indicate that bioactive ceramide analogues can be incorporated into pegylated liposomal vehicles for improved solubility, drug delivery, and antineoplastic efficacy.

Key Words: Liposome • Drug Delivery • Apoptosis • Pharmacokinetic • Breast Cancer

This article has been cited by other articles:

				M. A. Tran, R. Gowda, A. Sharma, E.-J. Park, J. Adair, M. Kester, N. B. Smith, and G. P. Robertson Targeting V600EB-Raf and Akt3 Using Nanoliposomal-Small Interfering RNA Inhibits Cutaneous Melanocytic Lesion Development Cancer Res., September 15, 2008; 68(18): 7638 - 7649. [Abstract] [Full Text] [PDF]

				B. S. Zolnik, S. T. Stern, J. M. Kaiser, Y. Heakal, J. D. Clogston, M. Kester, and S. E. McNeil Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo Drug Metab. Dispos., August 1, 2008; 36(8): 1709 - 1715. [Abstract] [Full Text] [PDF]

				Y. Sun, T. Fox, G. Adhikary, M. Kester, and E. Pearlman Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide J. Leukoc. Biol., June 1, 2008; 83(6): 1512 - 1521. [Abstract] [Full Text] [PDF]

				M. A. Tran, C. D. Smith, M. Kester, and G. P. Robertson Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development Clin. Cancer Res., June 1, 2008; 14(11): 3571 - 3581. [Abstract] [Full Text] [PDF]

				Y. H. Zeidan, R. W. Jenkins, and Y. A. Hannun Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway J. Cell Biol., April 21, 2008; 181(2): 335 - 350. [Abstract] [Full Text] [PDF]

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722. [Abstract] [Full Text] [PDF]

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, K. Sundararaj, Z. Szulc, J. Bielawski, A. Bielawska, M. Meyer, B. Cobanoglu, S. Koybasi, et al. Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1188 - 1199. [Abstract] [Full Text] [PDF]

				D. E. Modrak, D. V. Gold, and D. M. Goldenberg Sphingolipid targets in cancer therapy. Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208. [Abstract] [Full Text] [PDF]

				C. Voelkel-Johnson, Y. A. Hannun, and A. El-Zawahry Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein Mol. Cancer Ther., September 1, 2005; 4(9): 1320 - 1327. [Abstract] [Full Text] [PDF]